No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
301281 Shandong Keyuan Pharmaceutical
- 32.74
- -0.36-1.09%
Trading Dec 23 10:20 CST
3.55BMarket Cap70.71P/E (TTM)
33.10High32.10Low8.65KlotVolume33.06Open33.10Pre Close28.08MTurnover1.26%Turnover Ratio46.05P/E (Static)108.29MShares58.6652wk High2.65P/B2.25BFloat Cap18.5252wk Low39.72Limit Up68.85MShs Float63.69Historical High26.48Limit Down3.02%Amplitude18.52Historical Low0.30Dividend TTM32.46Avg Price4.83KlotAsk0.92%Div YieldTTM100Lot Size3.26KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Keyuan Pharmaceutical: Plans to purchase 99.42% equity of Hongjitang.
Kangyuan Pharmaceutical (301281.SZ): Currently not involved in medical consultation business.
Gelonghui November 5th, Ke Yuan Pharmaceuticals (301281.SZ) stated on the investor interaction platform that the company is mainly engaged in the research and development, production, and sales of chemical raw materials and their formulation products, and currently does not involve medical consulting businesses.
Express News | Kexin Pharmaceutical: Fully-owned subsidiary account at banks frozen.
Keyuan Pharmaceutical: Report for the third quarter of 2024
Express News | Three consecutive boardings of Keyuan Pharmaceutical: net income in the first three quarters decreased by 40.38% year-on-year.
Express News | Kelun Pharmaceutical: The net income in the first three quarters decreased by 40.38% year-on-year.
